CN114767847A - Novel crown recombinant protein vaccine adjuvant and application thereof - Google Patents
Novel crown recombinant protein vaccine adjuvant and application thereof Download PDFInfo
- Publication number
- CN114767847A CN114767847A CN202210710925.XA CN202210710925A CN114767847A CN 114767847 A CN114767847 A CN 114767847A CN 202210710925 A CN202210710925 A CN 202210710925A CN 114767847 A CN114767847 A CN 114767847A
- Authority
- CN
- China
- Prior art keywords
- recombinant protein
- vaccine
- adjuvant
- new crown
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The application relates to the technical field of biomedicine, in particular to a new crown recombinant protein vaccine adjuvant and application thereof, and provides application of long-chain thymic stromal lymphopoietin serving as the new crown recombinant protein vaccine adjuvant in preparation of new crown recombinant protein vaccines. The long-chain thymic stromal lymphopoietin is used as a new crown recombinant protein vaccine adjuvant, can promote the generation of antibodies, has stronger affinity to S1 protein and RBD protein of new crown virus, can effectively inhibit the combination of S1 protein and ACE2, and can effectively neutralize the combination of SARS-CoV-2 pseudovirus and ACE2, thereby preventing the virus from entering and infecting cells; in addition, the long-chain thymic stromal lymphopoietin is used as a vaccine adjuvant, has small side effect, is easy to store and can be widely used, and a new strategy is provided for the development of new crown recombinant protein vaccines.
Description
Technical Field
The application belongs to the technical field of biological medicines, and particularly relates to a new crown recombinant protein vaccine adjuvant and application thereof.
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, new coronavirus for short) is a single-stranded RNA virus of the family of beta-coronaviridae. The research finds that the new coronavirus envelope surface Spike protein (Spike protein, S) is combined with a host cell surface receptor Angiotensin-converting enzyme-2 (ACE 2), so that the virus invades the host cell. The S protein mainly comprises an N-terminal S1 subunit and a C-terminal S2 subunit, S1 is mainly responsible for binding of viruses and host receptors, S2 mainly plays a role of membrane fusion, and a Receptor Binding Domain (RBD) of the S1 subunit is a key region for directly binding ACE 2.
Because SARS-CoV-2 virus has very high mutation property, the prevention and control of epidemic situation caused by new crown virus mutant strain is still the first problem of world public health at present. Vaccination is the most economical and effective means of public health intervention for the prevention and control of infectious diseases. Therefore, the development of a safe and effective new corona vaccine is the most effective measure for preventing and stopping new corona pandemics.
At present, vaccines produced in China are inactivated vaccines, adenovirus vector vaccines and recombinant protein vaccines, wherein the recombinant protein vaccines have no live viruses, do not need to worry about the advantages of virus leakage and the like, and are easy to store, transport and the like. The recombinant protein vaccine generally consists of an antigen and an adjuvant, wherein the antigen generally selects S protein or RBD protein, so the adjuvant is a key link for successfully developing the SARS-CoV-2 recombinant protein vaccine.
Recent studies have found that aluminum adjuvant and MF59 can promote the production of specific and neutralizing antibodies of the new corona vaccine, but at the same time, obvious limitations are exposed and the mechanism of action is not completely clear. Such as: firstly, the aluminum salt and MF59 adjuvant mainly enhance systemic IgG antibodies and neutralizing antibodies aiming at new coronavirus S protein and RBD protein through muscle or subcutaneous immunization, but do not promote the generation of respiratory tract mucosa antibody IgA, which suggests that the adjuvant vaccine is not beneficial to inhibiting the spread infection of the new coronavirus; ② aluminum salt and MF59 adjuvant lack or induce weaker CD4+T and CD8+T cell response, which impairs the ability of cellular immunity against new coronaviruses; ③ the aluminum salt and the adjuvant MF59 have obvious side effects, and usually cause symptoms such as erythra, granuloma, headache, nerve diseases, etc. MF59 fusion inactivated vaccine immunization does not induce CD8+ T cell immunity, often leading to red swelling, fever, pain, stomach discomfort at the injection siteAnd the like. Fourthly, the aluminum adjuvant vaccine cannot be frozen and is not easy to store. Since the new coronavirus is mainly infected and spread through the respiratory tract, the mucous membrane of the respiratory tract becomes the first line of defense against the new coronavirus. The design of stable and efficient mucosal immune recombinant protein vaccines is one of the directions for researching new corona vaccines. And the selection of a proper mucosal immune adjuvant is the key for the successful development of a mucosal immune vaccine.
Disclosure of Invention
The application aims to provide a new crown recombinant protein vaccine adjuvant and application thereof, and aims to solve the problems that the common vaccine adjuvant of the new crown vaccine in the prior art weakens the capability of cellular immunity to resist new crown viruses and has larger side effect.
In order to achieve the purpose of the application, the technical scheme adopted by the application is as follows:
in a first aspect, the application provides an application of long-chain thymic stromal lymphopoietin as an adjuvant of a new crown recombinant protein vaccine in preparation of the new crown recombinant protein vaccine.
In a second aspect, the present application provides a novel crown recombinant protein vaccine adjuvant comprising long-chain thymic stromal lymphopoietin.
In a third aspect, the present application provides a novel corona vaccine comprising a novel corona recombinant protein vaccine adjuvant.
In a fourth aspect, the present application provides a method for preparing a novel corona vaccine, comprising the steps of:
respectively dissolving the new crown recombinant protein vaccine adjuvant and the immunogen in a buffer solution to obtain a new crown recombinant protein vaccine adjuvant buffer solution and an immunogen buffer solution;
and mixing the new crown recombinant protein vaccine adjuvant buffer solution and the immunogen buffer solution to prepare the new crown vaccine.
The application of the long-chain thymic stromal lymphopoietin provided by the first aspect of the application as an adjuvant of a new crown recombinant protein vaccine in preparing the new crown recombinant protein vaccine. Because the long-chain thymic stromal lymphopoietin is Interleukin (IL) -7-like cytokine derived from epithelial cells, the long-chain thymic stromal lymphopoietin mainly combines with heterodimer receptor complex consisting of TSLP receptor (TSLPR) and IL-7 receptor alpha chain (IL-7 Ra) to activate downstream signal transduction, and the long-chain thymic stromal lymphopoietin is taken as a new crown recombinant protein vaccine adjuvant, can promote the generation of antibodies, has stronger affinity to S1 protein and RBD protein of new crown virus, can effectively inhibit the combination of S1 protein and ACE2, and can effectively neutralize the combination of SARS-CoV-2 pseudovirus and ACE2, thereby preventing the virus from entering and infecting cells; in addition, the long-chain thymic stromal lymphopoietin is used as a vaccine adjuvant, has small side effect, is easy to store and can be widely used, and a new strategy is provided for the development of new crown recombinant protein vaccines.
The new crown recombinant protein vaccine adjuvant provided by the second aspect of the application comprises long-chain thymic stromal lymphopoietin. The vaccine obtained by taking the long-chain thymic stromal lymphopoietin as the new crown recombinant protein vaccine adjuvant can promote the generation of antibodies, has stronger affinity to S1 protein and RBD protein of new crown virus, can effectively inhibit the combination of S1 protein and ACE2, and can effectively neutralize the combination of SARS-CoV-2 pseudovirus and ACE2, thereby preventing the virus from entering and infecting cells; meanwhile, the immune response of cells can be enhanced, and the immune response has a better immune effect and higher biocompatibility.
The third aspect of the application provides a new corona vaccine, which comprises a new corona recombinant protein vaccine adjuvant, and the provided new corona recombinant protein vaccine adjuvant comprises long-chain thymic stromal lymphopoietin, so that the prepared new corona vaccine can effectively promote the generation of antibodies and prevent viruses from entering and infecting cells; meanwhile, the vaccine can enhance cellular immune response, has a good immune effect, is good in stability and high in safety, and is favorable for wide application.
The fourth aspect of the application provides a method for preparing a new corona vaccine, which comprises the steps of respectively providing a new corona recombinant protein vaccine adjuvant buffer solution and an immunogen buffer solution, and mixing to obtain the vaccine; the preparation method is simple and quick, and large-scale instruments and equipment do not need to be provided.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings needed to be used in the embodiments or the prior art descriptions will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
FIG. 1 is a timeline of nasal drop immunization of mice provided in the examples of the present application.
FIG. 2 is a graph of an assay of lfTSLP as an adjuvant to facilitate the production of antibodies specific to S1 protein, as provided in the examples herein.
FIG. 3 is a graph of the affinity and inhibition of S1/RBD using lfTSLP as an adjuvant provided in the examples of the present application.
FIG. 4 is a graph of a response analysis of the lfTSLP promotion vaccine specific development center provided in the examples of the present application.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present application more clearly apparent, the present application is further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are merely illustrative of and not restrictive on the broad application.
In this application, the term "and/or" describes an association relationship of associated objects, which means that there may be three relationships, for example, a and/or B, which may mean: a alone, A and B together, and B alone. Wherein A and B can be singular or plural. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship.
In the present application, "at least one" means one or more, "a plurality" means two or more. "at least one of the following" or similar expressions refer to any combination of these items, including any combination of the singular or plural items. For example, "at least one (a), b, or c", or "at least one (a), b, and c", may each represent: a, b, c, a-b (i.e. a and b), a-c, b-c, or a-b-c, wherein a, b, and c can be single or multiple respectively.
It should be understood that, in various embodiments of the present application, the sequence numbers of the above-mentioned processes do not mean the execution sequence, some or all of the steps may be executed in parallel or executed sequentially, and the execution sequence of each process should be determined by its function and inherent logic, and should not constitute any limitation to the implementation process of the embodiments of the present application.
The terminology used in the embodiments of the present application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. As used in the examples of this application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
The weight of the related components mentioned in the specification of the embodiments of the present application may not only refer to the specific content of each component, but also refer to the proportional relationship of the weight of each component, and therefore, the proportional enlargement or reduction of the content of the related components according to the specification of the embodiments of the present application is within the scope disclosed in the specification of the embodiments of the present application. Specifically, the mass in the description of the embodiments of the present application may be a unit of mass known in the chemical field, such as μ g, mg, g, kg, and the like.
The terms "first" and "second" are used for descriptive purposes only and are used for distinguishing purposes such as substances from one another, and are not to be construed as indicating or implying relative importance or implying any number of technical features indicated. For example, a first XX may also be referred to as a second XX, and similarly, a second XX may also be referred to as a first XX, without departing from the scope of embodiments of the present application. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature.
The first aspect of the embodiment of the application provides an application of long-chain thymic stromal lymphopoietin as an adjuvant of a new crown recombinant protein vaccine in preparation of the new crown recombinant protein vaccine.
The application of the long-chain thymic stromal lymphopoietin provided by the first aspect of the embodiment of the application as an adjuvant of a new crown recombinant protein vaccine in preparing the new crown recombinant protein vaccine. Because the long-chain thymic stromal lymphopoietin is an Interleukin (IL) -7-like cytokine derived from epithelial cells, the long-chain thymic stromal lymphopoietin mainly combines with a heterodimer receptor complex consisting of a TSLP receptor (TSLPR) and an IL-7 receptor alpha chain (IL-7 Ra) to activate downstream signal transduction, and as a new crown recombinant protein vaccine adjuvant, the long-chain thymic stromal lymphopoietin can promote the generation of antibodies, has stronger affinity to S1 protein and RBD protein of new crown viruses, can effectively inhibit the combination of the S1 protein and ACE2, and can effectively neutralize the combination of SARS-CoV-2 pseudovirus and ACE2, thereby preventing the viruses from entering and infecting cells; in addition, the long-chain thymic stromal lymphopoietin is used as a vaccine adjuvant, has small side effect, is easy to store and can be widely used, and a new strategy is provided for the development of new crown recombinant protein vaccines.
In some embodiments, a long-chain thymic stromal lymphopoietin (lfTSLP) is provided that is a subtype of thymic stromal lymphopoietin, and is a Interleukin (IL) -7-like cytokine of epithelial origin comprising 159 amino acids and capable of binding to a heterodimeric receptor complex consisting of TSLP receptor (TSLPR) and IL-7 receptor alpha chain (IL-7 ra) to activate downstream signaling.
In some embodiments, long-chain thymic stromal lymphopoietin inhibits viral infection by promoting respiratory mucosal antibody IgA production, inducing mucosal immunity.
In some embodiments, long-chain thymic stromal lymphopoietin is produced by induction of CD4+T cell, CD8+T cells and germinal centers react to enhance the cellular immunity against the new coronavirus.
In some embodiments, long-chain thymic stromal lymphopoietin induces vaccine-specific IgG1 antibody production to promote vaccine-specific germinal center responses.
In a second aspect, the embodiments of the present application provide a novel crown recombinant protein vaccine adjuvant, which includes long-chain thymic stromal lymphopoietin.
The novel crown recombinant protein vaccine adjuvant provided by the second aspect of the embodiment of the application comprises long-chain thymic stromal lymphopoietin. The vaccine obtained by taking the long-chain thymic stromal lymphopoietin as the new crown recombinant protein vaccine adjuvant can promote the generation of antibodies, has stronger affinity to S1 protein and RBD protein of new crown virus, can effectively inhibit the combination of S1 protein and ACE2, and can effectively neutralize the combination of SARS-CoV-2 pseudovirus and ACE2, thereby preventing the virus from entering and infecting cells; meanwhile, the immune response of cells can be enhanced, and the immune response has a better immune effect and higher biocompatibility.
In some embodiments, the novel crown recombinant protein vaccine adjuvant further comprises at least one of an aluminum adjuvant, MF59 adjuvant.
In some embodiments, the provided novel crown recombinant protein vaccine adjuvants include long-chain thymic stromal lymphopoietin and aluminum adjuvants.
In some embodiments, the provided novel crown recombinant protein vaccine adjuvants include long-chain thymic stromal lymphopoietin and MF59 adjuvant.
In some embodiments, the provided novel crown recombinant protein vaccine adjuvants include long-chain thymic stromal lymphopoietin, aluminum adjuvant, and MF59 adjuvant.
In a third aspect of the embodiments of the present application, there is provided a novel corona vaccine comprising a novel corona recombinant protein vaccine adjuvant.
The third aspect of the embodiment of the application provides a new corona vaccine, which comprises a new corona recombinant protein vaccine adjuvant, and the provided new corona recombinant protein vaccine adjuvant comprises long-chain thymic stromal lymphopoietin, so that the prepared new corona vaccine can effectively promote the generation of antibodies and prevent viruses from entering and infecting cells; meanwhile, the vaccine can enhance cellular immune response, has a good immune effect, is good in stability and high in safety, and is beneficial to wide application.
In some embodiments, the novel corona vaccine further comprises an immunogen, wherein the immunogen comprises a novel corona virus immunogen.
In some embodiments, the molar ratio of the adjuvant to the immunogen in the new corona vaccine is 1-1.1: 1 to 1.1.
In some embodiments, the molar ratio of the new corona recombinant protein vaccine adjuvant to the immunogen is 1: 1.
in a fourth aspect, the embodiments of the present application provide a method for preparing a novel corona vaccine, comprising the following steps:
s01, respectively dissolving the new crown recombinant protein vaccine adjuvant and the immunogen in a buffer solution to obtain a new crown recombinant protein vaccine adjuvant buffer solution and an immunogen buffer solution;
s02, mixing the new crown recombinant protein vaccine adjuvant buffer solution and the immunogen buffer solution to prepare the new crown vaccine.
The fourth aspect of the embodiment of the application provides a method for preparing a new corona vaccine, which comprises the steps of respectively providing an adjuvant buffer solution and an immunogen buffer solution of the new corona recombinant protein vaccine, and mixing to obtain the vaccine; the preparation method is simple and quick, and large-scale instruments and equipment do not need to be provided.
In step S01, the buffer is selected from PBS buffer.
In some embodiments, the novel corona recombinant protein vaccine adjuvant is selected from long-chain thymic stromal lymphopoietin.
In some embodiments, the immunogen is selected from the novel coronavirus S1 protein.
Further, the new crown recombinant protein vaccine adjuvant and the immunogen are respectively dissolved in a buffer solution to obtain a new crown recombinant protein vaccine adjuvant buffer solution and an immunogen buffer solution.
In step S02, mixing the new crown recombinant protein vaccine adjuvant buffer solution and the immunogen buffer solution, wherein the molar ratio of the provided new crown recombinant protein vaccine adjuvant buffer solution to the immunogen buffer solution is 1: 1.
the following description will be given with reference to specific examples.
Example 1
New corona vaccine and preparation method thereof
The provided new corona vaccine comprises a new corona recombinant protein vaccine adjuvant long-chain thymic stromal lymphopoietin and immunogen novel coronavirus S1 protein.
The preparation method of the novel corona vaccine comprises the following steps:
respectively dissolving long-chain thymic stromal lymphopoietin serving as an adjuvant of the new crown recombinant protein vaccine and novel coronavirus S1 protein serving as an immunogen in a PBS (phosphate buffer solution) to obtain a buffer solution serving as the adjuvant of the new crown recombinant protein vaccine and a buffer solution serving as the immunogen;
the new crown recombinant protein vaccine adjuvant buffer solution and the immunogen buffer solution are mixed according to a molar ratio of 1: 1 (namely 2 mug of new crown recombinant protein vaccine adjuvant and 2 mug of immunogen) to prepare the new crown vaccine.
Performance testing
Vaccine immunization experiment
12 purchased C57BL/6 mice each weighing 20g were randomly divided into 2 groups (group A, B). The mice in group A were subjected to nasal drip immunization for 30. mu.L of S1 protein (2. mu.g), the mice in group B were subjected to nasal drip immunization for 30. mu.L of the novel corona vaccine prepared in example 1 (i.e., the adjuvant of the novel corona recombinant protein vaccine is 2. mu.g, and the immunogen is 2. mu.g), immunization was performed once every 10 days for 3 times, and all mice were subjected to periocular vein bleeding on day 10 after the third immunization, and serum was collected by centrifugation. Mice were euthanized, spleens, lymph nodes were dissected and collected, and lungs were lavaged with 500 μ L PBS for detection of respiratory mucosal IgA.
(II) ELISA method for detecting serum specific IgG and IgA after immunization
ELISA method for detecting serum specific IgG after immunization
1) Preparing antigen S1 or RBD (6. mu.g/mL) with PBS (4. mu.g/mL of final concentration), adding 100. mu.L/well antigen protein into the high-adsorption eight-well enzyme label strip, coating overnight at 4 ℃, discarding liquid, and washing with 200. mu.L PBST for 5 times;
2) adding 200 μ L blocking solution (5% BSA), blocking at room temperature for 2 hr, discarding the solution, and washing with 200 μ L PBST for 5 times;
3) adding 100 μ L/well diluted serum, incubating at room temperature for 1h, discarding liquid, and washing with 200 μ L PBS for 5 times;
4) add 100. mu.L per well as mix 1: Anti-IgG (H + L) -HRP diluted at 2000, gently shaken at room temperature for 1H and then antibody discarded and washed 5 times with 200. mu.L PBST;
5) the addition of 100. mu.L of TMB substrate, gentle shaking at room temperature until the sample clearly developed a blue color, followed by the addition of 100. mu.L of 1M HCl to stop the reaction and determine its OD at OD450 nm.
② ELISA method for detecting serum specificity IgA after immunization
1) Preparing antigen S1 or RBD (6 mug/mL) with a final concentration of 4 mug/mL by PBS, adding 100 mug/well antigen protein into a high-adsorption eight-well enzyme label strip, discarding liquid after coating overnight at 4 ℃, and washing 5 times by 200 mug PBST;
2) adding 200 μ L blocking solution (5% BSA), blocking at room temperature for 2 hr, discarding the solution, and washing with 200 μ L PBST for 5 times;
3) adding 100 μ L/well diluted serum, incubating at room temperature for 1h, discarding liquid, and washing with 200 μ L PBS for 5 times;
4) add 100. mu.L per well as 1: 2000 diluted Anti-IgA-HRP, gently shaking for 1h at room temperature, discarding the antibody and washing 5 times with 200 μ L PBST;
the addition of 100. mu.L of TMB substrate, shaking slightly at room temperature until the sample clearly developed a blue color, followed by the addition of 100. mu.L of 1M HCl to stop the reaction and to determine its OD at OD450 nm.
(III) competitive ELISA method for detecting inhibition effect of serum on binding of S1 and ACE2
1) Preparing hACE2-mFC with PBS to the final concentration of 6 mug/mL, adding 100 mug/hole in a high-adsorption eight-hole enzyme label strip, discarding liquid after coating overnight at 4 ℃, and washing 5 times with 200 mug PBST;
2) adding 200 μ L blocking solution (5% BSA), blocking at room temperature for 2 hr, discarding the solution, and washing with 200 μ L PBST for 5 times;
3) the diluted sera were mixed with S1 (final concentration 6. mu.g/mL); adding the control group without serum, mixing, adding into sealed 96-well plate, incubating at 37 deg.C for 1h, discarding liquid, and washing with 200 μ L PBST for 5 times;
4) add 100. mu.L per well as 1: 3000 diluted Anti-His-HRP, gently shaking for 1h at room temperature, discarding the antibody and washing 5 times with 200. mu.L PBST;
5) the addition of 100. mu.L of TMB substrate, gentle shaking at room temperature until the sample clearly developed a blue color, followed by the addition of 100. mu.L of 1M HCl to stop the reaction and determine its OD at OD450 nm.
(IV) detecting the binding effect of serum neutralization SARS-CoV-2 pseudovirus and ACE2
1) Cell plating: HEK293T-ACE2 cells to be infected were seeded in 96 well cell culture plates at approximately 2X 104In the case of overnight culture in an incubator, the cell inoculation density is about 30% when virus infection is carried out the next day;
2) melting SARS-CoV-2-GFP pseudovirus and serum at 4 deg.C, mixing and incubating at room temperature for 1 h; (serum was diluted 2-fold, 4-fold, 8-fold with DMEM complete medium respectively; final concentration of pseudovirus was 6.3X 104 TU/mL)；
3) Taking out and extracting paved HEK293T-ACE2 cells, discarding an upper layer culture medium, sucking 100 mu L of incubated pseudovirus-serum mixed solution into a 96-well plate paved with HEK293T-ACE2 cells, repeating three wells, infecting for 6 hours in a cell culture box, changing a fresh DMEM complete culture medium, continuously culturing for 48 hours, and observing the infection condition of the pseudovirus by using a fluorescence microscope.
(V) detecting the reaction of the vaccine specific generation center by flow cytometry
1) Taking the spleen of the immunized mouse for three times, grinding lymph nodes into single cell suspension, transferring the single cell suspension into a 96-hole round bottom plate, and centrifuging (5min,1500 rpm);
2) and (3) sealing: 3% BSA was formulated in PBS and 50. mu.L of the BSA solution at 1: 1000 dilution of CD16/32, blocking at 4 ℃ for 30min, centrifugation (5min,1500 rpm);
3) dyeing: using PE-labeled anti-murine CD19 antibody, PE/CY 7-labeled anti-murine CD4 antibody, FITC-labeled anti-murine PD1 antibody, APC-labeled anti-murine CXCR5 antibody, Pacific Blue-labeled anti-murine GL7 antibody, PerCP-CY 5.5-labeled anti-murine FAS antibody, BV 605-labeled anti-murine B220 antibody and AF 700-labeled anti-murine CD44 antibody (all antibodies were purchased from Biolegend), antibody staining of cells, staining at 4 ℃ for 30min, centrifugation (5min,1500 rpm);
4) cell fluorescence was detected on a flow cytometer.
(VI) flow cytometry detection of changes in DCs
1) Taking lymph nodes of the mice 5 days after the secondary immunization, grinding into single cell suspension, transferring into a 96-hole round bottom plate, and centrifuging (5min,1500 rpm);
2) and (3) sealing: 3% BSA was formulated in PBS and 50. mu.L of the BSA solution at 1: 1000 dilution of CD16/32, blocking at 4 ℃ for 30min, centrifugation (5min,1500 rpm);
3) dyeing: using BV 605-labeled anti-murine CD11c antibody, AF 700-labeled anti-murine IA/IE antibody, FITC-labeled anti-murine CD103 antibody, PE-labeled anti-murine CD80 antibody, (all antibodies were purchased from Biolegend), antibody staining of cells, staining at 4 ℃ for 30min, centrifugation (5min,1500 rpm);
4) cell fluorescence was detected on a flow cytometer.
Analysis of results
Vaccine immunization experiment
As shown in fig. 1, the time axis of nasal drop immunized mice shows that, at the cell layer level, lfTSLP can effectively neutralize the binding of the novel coronavirus and ACE2, and reduce virus-infected cells; it was further revealed by flow cytometry that lfTSLP can promote vaccine-specific germinal center responses. The results show that lfTSLP can be used as a novel mucosal adjuvant to play an important role in a new crown recombinant protein vaccine.
(II) ELISA method for detecting serum specific IgG and IgA after immunization
In order to detect the level of specific antibodies in serum, mice were subjected to nasal drip immunization and blood was collected according to the time axis of (fig. 1), and serum after three nasal drip immunization was detected by ELISA method, and the result is shown in fig. 2, in which a in fig. 2 is the level of S1 specific IgG antibodies in serum after three immunization; b in FIG. 2 is the level of RBD-specific IgG antibodies in serum after three immunizations; c of FIG. 2 is the level of S1-specific IgA antibodies in serum after three immunizations; FIG. 2D is the level of RBD-specific IgA antibodies in serum after three immunizations; it can be seen that lfTSLP can promote the production of S1-specific antibody IgG (FIG. 2A) IgA (FIG. 2C), RBD-specific antibody IgG (FIG. 2B) IgA (FIG. 2D).
Affinity and inhibitory Effect of (tri) lfTSLP as an adjuvant on S1/RBD
In order to explore the affinity of the adjuvant on S1/RBD and the inhibition effect on the binding of S1 and hACE2, the affinity is analyzed by an ELISA method, and a fold-diluted serum is added into coated S1/RBD for reaction, as shown in FIG. 3, wherein A in FIG. 3 is the affinity of the serum and S1 analyzed by the ELISA method; FIG. 3B shows the ELISA method for analyzing the affinity of serum to RBD; FIG. 3C shows the inhibition of S1 binding to hACE2 in serum analyzed by competitive ELISA, and IC50 shows the inhibition rate of serum antibodies; FIG. 3D shows the observation under the microscope of the fluorescence of GFP after infection of HEK293T-ACE2 cells for 48 h after incubation of SARS-CoV-2 pseudovirus with serum at different dilutions.
The results show that lfTSLP has stronger affinity for S1 (FIG. 3A), RBD (FIG. 3B); the inhibition effect of S1 on hACE2 was analyzed by a competitive ELISA method, serum fold-rate dilution and S1 with the final concentration of 6. mu.g/mL were mixed uniformly and added to the coated hACE2 together for reaction, and the result shows that lfTSLP has an inhibition effect on the binding of S1 and hACE2 (FIG. 3C); to test the neutralizing effect of lfTSLP on SARS-CoV-2 pseudovirus into ACE2 overexpressing cell line, serum with different dilution times was used to incubate SARS-CoV-2 pseudovirus with GFP and added to ACE2 overexpressing HEK293T cells for culture; GFP fluorescence was observed under a microscope after 48 h (FIG. 3D), and the results showed that the more serum, the less fluorescence, indicating that lfTSLP had a significant effect of inhibiting the binding of SARS-CoV-2 pseudovirus to ACE2 and into cells.
(IV) lfTSLP promotes vaccine-specific germinal center response
In order to explore the mechanism of lfTSLP in promoting antibody production, spleen and lymph nodes of mice after three immunizations were analyzed by flow cytometry, and the results are shown in fig. 4, in which a in fig. 4 is the ratio of Tfh cells in spleen and lymph nodes of mice after three immunizations; FIG. 4B is the ratio of GC B cells in the spleen and lymph nodes of mice after three immunizations; FIG. 4C is the proportion of DC cells in the lymph nodes of mice 5 days after the secondary immunization.
It can be seen that lfTSLP can increase the proportion of Tfh cells (fig. 4A), GC B cells (fig. 4B); the lymph nodes of mice 5 days after secondary immunization were also analyzedIt was found that lfTSLP can promote CD103+Increase in the ratio (fig. 4C).
In conclusion, the long-chain thymic stromal lymphopoietin provided by the application is used as an adjuvant of a new crown recombinant protein vaccine in the preparation of the new crown recombinant protein vaccine. Because the long-chain thymic stromal lymphopoietin is Interleukin (IL) -7-like cytokine derived from epithelial cells, the long-chain thymic stromal lymphopoietin mainly combines with heterodimer receptor complex consisting of TSLP receptor (TSLPR) and IL-7 receptor alpha chain (IL-7 Ra) to activate downstream signal transduction, and the long-chain thymic stromal lymphopoietin is taken as a new crown recombinant protein vaccine adjuvant, can promote the generation of antibodies, has stronger affinity to S1 protein and RBD protein of new crown virus, can effectively inhibit the combination of S1 protein and ACE2, and can effectively neutralize the combination of SARS-CoV-2 pseudovirus and ACE2, thereby preventing the virus from entering and infecting cells; in addition, the long-chain thymic stromal lymphopoietin is used as a vaccine adjuvant, has small side effect, is easy to store and can be widely used, and a new strategy is provided for the development of new crown recombinant protein vaccines.
The above description is only exemplary of the present application and should not be taken as limiting the present application, as any modification, equivalent replacement, or improvement made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (10)
1. The application of long-chain thymus stromal lymphopoietin as an adjuvant of new crown recombinant protein vaccine in preparing new crown recombinant protein vaccine.
2. The use of claim 1, wherein said long-chain thymic stromal lymphopoietin inhibits viral infection by promoting respiratory mucosal antibody IgA production, inducing mucosal immunity.
3. The use of claim 1, wherein said long-chain thymic stromal lymphopoietin is produced by induction of CD4+T cells and CD8+T cells and germinal centers react,enhancing the capability of cellular immunity to resist new coronavirus.
4. The use of claim 1, wherein the long-chain thymic stromal lymphopoietin induces vaccine-specific IgG1 antibody production to promote vaccine-specific germinal center response.
5. A new crown recombinant protein vaccine adjuvant is characterized in that the new crown recombinant protein vaccine adjuvant comprises long-chain thymic stromal lymphopoietin.
6. The neocorona recombinant protein vaccine adjuvant of claim 5, further comprising at least one of an aluminum adjuvant and an MF59 adjuvant.
7. A novel corona vaccine, comprising the novel corona recombinant protein vaccine adjuvant of any one of claims 5-6.
8. The neo-corona vaccine according to claim 7, further comprising an immunogen, wherein said immunogen comprises a neo-corona virus immunogen.
9. The neo-corona vaccine according to any one of claims 7 to 8, wherein the molar ratio of the neo-corona recombinant protein vaccine adjuvant to the immunogen is 1 to 1.1: 1 to 1.1.
10. The method for preparing the novel corona vaccine of any one of claims 7 to 9, comprising the steps of:
respectively dissolving the new crown recombinant protein vaccine adjuvant and the immunogen in a buffer solution to obtain a new crown recombinant protein vaccine adjuvant buffer solution and an immunogen buffer solution;
and mixing the new crown recombinant protein vaccine adjuvant buffer solution and the immunogen buffer solution to prepare the new crown vaccine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210710925.XA CN114767847B (en) | 2022-06-22 | 2022-06-22 | Novel crown recombinant protein vaccine adjuvant and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210710925.XA CN114767847B (en) | 2022-06-22 | 2022-06-22 | Novel crown recombinant protein vaccine adjuvant and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114767847A true CN114767847A (en) | 2022-07-22 |
| CN114767847B CN114767847B (en) | 2022-09-23 |
Family
ID=82422274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210710925.XA Active CN114767847B (en) | 2022-06-22 | 2022-06-22 | Novel crown recombinant protein vaccine adjuvant and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114767847B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115894713A (en) * | 2022-09-22 | 2023-04-04 | 武汉滨会生物科技股份有限公司 | Heterotrimeric fusion proteins, compositions and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011051657A1 (en) * | 2009-10-26 | 2011-05-05 | St George's Hospital Medical School | Thymic stromal lymphopoietin as an adjuvant for a vaccine |
| CN103961701A (en) * | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | Vaccine composition |
| CN111892648A (en) * | 2020-06-08 | 2020-11-06 | 中国科学院上海药物研究所 | Novel coronavirus polypeptide vaccine coupled with TLR7 agonist and application thereof |
| CN113713093A (en) * | 2021-08-31 | 2021-11-30 | 中国人民解放军陆军军医大学 | Novel tretinoin nanoemulsion adjuvant capable of efficiently enhancing humoral immune response and mucosal immune response and preparation method and application thereof |
| WO2022094475A1 (en) * | 2020-11-02 | 2022-05-05 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
-
2022
- 2022-06-22 CN CN202210710925.XA patent/CN114767847B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011051657A1 (en) * | 2009-10-26 | 2011-05-05 | St George's Hospital Medical School | Thymic stromal lymphopoietin as an adjuvant for a vaccine |
| CN103961701A (en) * | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | Vaccine composition |
| US20140220063A1 (en) * | 2013-02-05 | 2014-08-07 | Nitto Denko Corporation | Vaccine composition |
| CN111892648A (en) * | 2020-06-08 | 2020-11-06 | 中国科学院上海药物研究所 | Novel coronavirus polypeptide vaccine coupled with TLR7 agonist and application thereof |
| WO2022094475A1 (en) * | 2020-11-02 | 2022-05-05 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
| CN113713093A (en) * | 2021-08-31 | 2021-11-30 | 中国人民解放军陆军军医大学 | Novel tretinoin nanoemulsion adjuvant capable of efficiently enhancing humoral immune response and mucosal immune response and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| GRIET A. VAN ROEY: "Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice", 《EUR. J. IMMUNOL.》 * |
| S JOO: "Critical role of TSLP-responsive mucosal dendritic cells in the induction of nasal antigen-specific IgA response", 《MUCOSAL IMMUNOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115894713A (en) * | 2022-09-22 | 2023-04-04 | 武汉滨会生物科技股份有限公司 | Heterotrimeric fusion proteins, compositions and uses thereof |
| CN115894713B (en) * | 2022-09-22 | 2023-08-01 | 武汉滨会生物科技股份有限公司 | Heterotrimeric fusion proteins, compositions and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114767847B (en) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11701420B2 (en) | Parenteral norovirus vaccine formulations | |
| Cook et al. | Equine infectious anemia and equine infectious anemia virus in 2013: a review | |
| Selin et al. | Heterologous immunity: immunopathology, autoimmunity and protection during viral infections | |
| CN102070704B (en) | Entire gene sequence of severe fever with thrombocytopenia syndrome virus (SFTSV) and application | |
| TWI579297B (en) | Combined vaccines for prevention of porcine virus infections | |
| Hickman et al. | The effect of malnutrition on norovirus infection | |
| CN104962581B (en) | A kind of recombinant viral vaccine strain for expressing African swine fever virus p72 albumen | |
| Durando et al. | Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and-seronegative adults | |
| CN114767847B (en) | Novel crown recombinant protein vaccine adjuvant and application thereof | |
| Grewal et al. | Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection | |
| CN102399757A (en) | Immunogenic compositions and uses thereof | |
| CN106947745A (en) | The type strain WF057R of Coxsackie virus A 6 and its application | |
| CN106867974A (en) | Type infected animal model of CA 6 and preparation method and application | |
| Sulbaran et al. | Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection | |
| Göncüoğlu et al. | Emerging details about COVID-19 and chronology of the pandemic in Turkey | |
| CN106018780A (en) | F1-protein-based indirect immunofluorescence kit for detecting type 4 fowl adenovirus antibody | |
| CN106994182A (en) | Prevent and treat vaccine of Coxsackie virus associated diseases and preparation method and application | |
| CN107653231B (en) | Duck-origin coronavirus low-virulent strain IBVDCV35 and application thereof | |
| Lassauniere et al. | Neutralisation of SARS-CoV-2 Omicron subvariants BA. 2.86 and EG. 5.1 by antibodies induced by earlier infection or vaccination | |
| CN105296507A (en) | Lassa fever virus-like particles as well as preparation method and application thereof | |
| CN105218679A (en) | Human metapneumovirus multi-epitope antigen and application thereof | |
| Rautenschlein et al. | Infectious bronchitis: 80 years of control efforts to combat a Coronavirus infection in poultry | |
| CN111249308A (en) | Application of CAR-T technology in preventing and treating coronavirus infectious diseases | |
| KR20200061508A (en) | An attenuated avian metapneumovirus and a vaccine composition including the same | |
| CN109554391A (en) | The method and recombined adhenovirus and application of toxoplasma SAG2 gene and the building of ROP9 gene recombinant adenovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |